Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of molnupiravir and the impact the UK approval has already had on the COVID-19 pandemic response.
The abstract ‘Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): findings from the United Kingdom randomised, controlled open-label, platform adaptive trial.‘ (Abstract number: O1118) was presented at ECCMID 2023, 15-18 April, 2023, Copenhagen, Denmark.
Questions
- What is the mechanism of action of molnupiravir and why is it indicated in early stages of infection? (0:22)
- What impact has the UK approval of molnupiravir already had on the COVID-19 pandemic response? (1:07)
Disclosures: Chris Butler discloses being the Chief Investigator of the NIHR funded PRINCIPLE and PANORAMIC trials of community treatment for COVID.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch and Victoria Jones.
Filmed in coverage of the 33rd European Congress of Clinical Microbiology & Infectious Diseases.
Click here for more content on COVID-19 & for further ECCMID 2023 highlights visit here.
